JP2022505637A5 - - Google Patents

Info

Publication number
JP2022505637A5
JP2022505637A5 JP2021522048A JP2021522048A JP2022505637A5 JP 2022505637 A5 JP2022505637 A5 JP 2022505637A5 JP 2021522048 A JP2021522048 A JP 2021522048A JP 2021522048 A JP2021522048 A JP 2021522048A JP 2022505637 A5 JP2022505637 A5 JP 2022505637A5
Authority
JP
Japan
Prior art keywords
compound
salt according
inhibitors
hiv
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505637A (ja
JP7532354B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059018 external-priority patent/WO2020084491A1/en
Publication of JP2022505637A publication Critical patent/JP2022505637A/ja
Publication of JP2022505637A5 publication Critical patent/JP2022505637A5/ja
Application granted granted Critical
Publication of JP7532354B2 publication Critical patent/JP7532354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522048A 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7532354B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749801P 2018-10-24 2018-10-24
US62/749,801 2018-10-24
PCT/IB2019/059018 WO2020084491A1 (en) 2018-10-24 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505637A JP2022505637A (ja) 2022-01-14
JP2022505637A5 true JP2022505637A5 (cg-RX-API-DMAC7.html) 2022-11-01
JP7532354B2 JP7532354B2 (ja) 2024-08-13

Family

ID=68344932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522048A Active JP7532354B2 (ja) 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (5)

Country Link
US (1) US20210395262A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870576B1 (cg-RX-API-DMAC7.html)
JP (1) JP7532354B2 (cg-RX-API-DMAC7.html)
ES (1) ES2971987T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020084491A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
ES2969030T3 (es) * 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) * 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
JP7361766B2 (ja) * 2018-09-14 2023-10-16 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020058844A1 (en) * 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
PT3870575T (pt) * 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤

Similar Documents

Publication Publication Date Title
JP2022505597A5 (cg-RX-API-DMAC7.html)
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2022505989A5 (cg-RX-API-DMAC7.html)
JP2022500425A5 (cg-RX-API-DMAC7.html)
JP2022501370A5 (cg-RX-API-DMAC7.html)
ES2670769T3 (es) Derivados de (hetero)arilacetamida como agentes antirretrovirales
CA3089590A1 (en) Pyridine derivatives and their use for treating hiv infection
JPWO2023054292A5 (cg-RX-API-DMAC7.html)
JP2006506425A5 (cg-RX-API-DMAC7.html)
JP2022081661A5 (cg-RX-API-DMAC7.html)
RU2001132635A (ru) Производные пиперидина, применимые в качестве антагонистов сс R5
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2025508656A5 (cg-RX-API-DMAC7.html)
CA2541781A1 (en) 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses
JP2023544716A5 (cg-RX-API-DMAC7.html)
JP2023512664A5 (cg-RX-API-DMAC7.html)
RU2008142598A (ru) Селективные гидроксаматные ингибиторы ммп
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
RU2007105582A (ru) Агонисты рецепторов никотина и способы их применения для лечения воспалительных заболеваний
ES2733756T3 (es) Agentes terapéuticos para el tratamiento de hipertensión ocular
CN100475209C (zh) 抗冠状病毒剂
JP7136910B2 (ja) 乾性眼の予防または治療のための組成物
JP2025507308A5 (cg-RX-API-DMAC7.html)
EP1521581B1 (en) Diarylmethylpiperazines as prophylactic or therapeutic agents for viral myocarditis